Pacira BioSciences Inc (PCRX)
25.90
-0.91
(-3.39%)
USD |
NASDAQ |
Apr 24, 16:00
25.91
+0.01
(+0.04%)
After-Hours: 20:00
Pacira BioSciences Research and Development Expense (Quarterly): 19.46M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 19.46M |
| September 30, 2023 | 20.83M |
| June 30, 2023 | 18.82M |
| March 31, 2023 | 17.14M |
| December 31, 2022 | 17.50M |
| September 30, 2022 | 19.40M |
| June 30, 2022 | 26.28M |
| March 31, 2022 | 21.60M |
| December 31, 2021 | 15.51M |
| September 30, 2021 | 11.58M |
| June 30, 2021 | 12.57M |
| March 31, 2021 | 15.88M |
| December 31, 2020 | 15.33M |
| September 30, 2020 | 14.65M |
| June 30, 2020 | 13.62M |
| March 31, 2020 | 15.82M |
| December 31, 2019 | 19.65M |
| September 30, 2019 | 20.26M |
| June 30, 2019 | 17.83M |
| March 31, 2019 | 14.38M |
| December 31, 2018 | 14.17M |
| September 30, 2018 | 14.90M |
| June 30, 2018 | 12.24M |
| March 31, 2018 | 14.38M |
| December 31, 2017 | 10.03M |
| Date | Value |
|---|---|
| September 30, 2017 | 11.78M |
| June 30, 2017 | 18.86M |
| March 31, 2017 | 16.63M |
| December 31, 2016 | 17.07M |
| September 30, 2016 | 9.754M |
| June 30, 2016 | 9.362M |
| March 31, 2016 | 9.493M |
| December 31, 2015 | 13.15M |
| September 30, 2015 | 5.893M |
| June 30, 2015 | 3.649M |
| March 31, 2015 | 5.967M |
| December 31, 2014 | 3.887M |
| September 30, 2014 | 4.425M |
| June 30, 2014 | 5.216M |
| March 31, 2014 | 5.204M |
| December 31, 2013 | 4.836M |
| September 30, 2013 | 5.962M |
| June 30, 2013 | 4.857M |
| March 31, 2013 | 5.905M |
| December 31, 2012 | 3.244M |
| September 30, 2012 | 3.527M |
| June 30, 2012 | 1.872M |
| March 31, 2012 | 1.294M |
| December 31, 2011 | 2.131M |
| September 30, 2011 | 4.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.58M
Minimum
Sep 2021
26.28M
Maximum
Jun 2022
17.57M
Average
17.50M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Dynavax Technologies Corp | 14.12M |
| Arbutus Biopharma Corp | 17.56M |
| Chimerix Inc | 15.64M |
| Karyopharm Therapeutics Inc | 39.38M |
| FibroGen Inc | 51.70M |